Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome

Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes

¹Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
²Division of Diabetes and Endocrinology, City of Hope Medical Center, Duarte, California
³Centers for Disease Control and Prevention, Atlanta, Georgia

Address correspondence and reprint requests to Bobby V. Khan, MD, PhD, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Dr. SE, #C247, Atlanta, GA 30303. E-mail: bkhan{at}emory.edu

Diabetes Care 2004 Jul; 27(7): 1712-1715. https://doi.org/10.2337/diacare.27.7.1712

Article Figures & Tables

Table 1—

Diagnostic criteria for the metabolic syndrome

Factor	Criteria
1	Abdominal girth >40 in (102 cm) in men or >35 in (88 cm) in women
2	HDL cholesterol <40 mg/dl in men or <50 mg/dl in women
3	Fasting triglycerides >150 mg/dl (1.69 mmol/l)
4	Blood pressure >130/85 mmHg
5	Fasting glucose ≥110 mg/dl (≥ 6.1 mmol/l)

Three out of five criteria are required for diagnosis of the metabolic syndrome.

Table 2—

Patient demographics and baseline characteristics

	Quinapril	Placebo
n	20	20
Age (years)	35.2	39.6
Sex (M/F)	11/9	12/8
BMI (kg/m²)	29.8	29.1
Systolic blood pressure (mmHg)	126 ± 8	130 ± 9
Diastolic blood pressure (mmHg)	80 ± 10.4	77.8 ± 11.1
LDL cholesterol (mg/dl)	124.7 ± 21.4	130 ± 16.8
HDL cholesterol (mg/dl)	40.3 ± 7.0	38.9 ± 6.1
Triglycerides (mg/dl)	238 ± 36	219 ± 30
Fasting glucose (mg/dl)	113 ± 15	111 ± 19
HbA_1c (%)	5.8 ± 0.7	5.6 ± 0.8
Hypertension	5 (25)	6 (30)
Smoking history	7 (35)	6 (30)
Concomitant medications
Lipid lowering therapy*	5 (25)	6 (30)
β-Blocker	2 (10)	4 (20)
Diuretic	3 (15)	4 (20)
Calcium channel blocker	3 (15)	4 (20)

Table 3—

Effects of therapy on markers of oxidative stress and metabolic indexes